M.; Joseph, P.; Hale, B.; Beyersmann, D. Molecular and cellular mechanisms of cadmium carcinogenesis. Toxicology 2003, 192, 9517. 39. Bursch, W.; Karwan, A.; Mayer, M.; Dornetshuber, J.; Fr wein, U.; Schulte-Hermann, R.; Fazi, B.; Di Sano, F.; Piredda, L.; Piacentini, M.; et al. Cell death and autophagy: Cytokines, drugs, and nutritional components. Toxicology 2008, 254, 14757. 40. Singh, R.; Saini, N. Downregulation of BCL2 by miRNAs augments drug-induced apoptosis–A combined computational and experimental strategy. J. Cell Sci. 2012, 125, 1568578. 41. Matsuoka, M.; Igisu, H. Cadmium Induces Phosphorylation of p53 at Serine 15 in MCF-7 Cells. Biochem. Biophys. Res. Commun. 2001, 282, 1120125. 42. Cheok, C.F.; Verma, C.S.; Baselga, J.; Lane, D.P. Translating p53 into the clinic. Nat. Rev. Clin. Oncol. 2011, eight, 257. 43. Cheok, C.F.; Lane, D.P. Searching for synergy in p53 transcriptional activation for cancer therapy. Discov. Med. 2012, 14, 26371. 44. Martins, C.P.; Brown-Swigart, L.; Evan, G.I. Modeling the therapeutic efficacy of p53 restoration in tumors. Cell 2006, 127, 1323334.Int. J. Mol. Sci. 2013,45. Ventura, A.; Kirsch, D.G.; McLaughlin, M.E.; Tuveson, D.A.; Grimm, J.; Lintault, L.; Newman, J.; Reczek, E.E.; Weissleder, R.; Jacks, T. Restoration of p53 function results in tumour regression in vivo. Nature 2007, 445, 66165. 46. Xue, C.; Haber, M.; Flemming, C.; Marshall, G.M.; Lock, R.B.; MacKenzie, K.L.; Gurova, K.V.; Norris, M.D.; Gudkov, A.V. p53 determines multidrug sensitivity of childhood neuroblastoma. Cancer Res. 2007, 67, 103510360. 47. Dang, C.V. MYC on the path to cancer. Cell 2012, 149, 225. 48. Gurel, B.; Iwata, T.; Koh, C.M.; Jenkins, R.B.; Lan, F.; Van Dang, C.; Hicks, J.L.; Morgan, J.; Cornish, T.C.; Sutcliffe, S.; et al. Nuclear MYC protein overexpression is an early alteration in human prostate carcinogenesis. Mod. Pathol. 2008, 21, 1156167. 49. Palaskas, N.; Larson, S.M.; Schultz, N.; Komisopoulou, E.; Wong, J.; Rohle, D.; Campos, C.; Yannuzzi, N.; Osborne, J.R.; Linkov, I.; et al. 18F-fluorodeoxy-glucose positron emission tomography marks MYC-overexpressing human basal-like breast cancers. Cancer Res. 2011, 71, 5164174. 50. Chan, C.B.; Liu, X.; Jang, S.W.; Hsu, S.I.H.; Williams, I.; Kang, S.; Chen, J.; Ye, K. NGF inhibits human leukemia proliferation by downregulatingcyclin A1 expression by means of advertising acinus/CtBP2 association. Oncogene 2009, 28, 3825836. 51. Marlow, L.A.; von Roemeling, C.A.; Cooper, S.J.; Zhang, Y.Dehydroabietic acid ; Rohl, S.Moclobemide D.PMID:28739548 ; Arora, S.; Gonzales, I.M.; Azorsa, D.O.; Reddi, H.V.; Tun, H.W.; et al. Foxo3a drives proliferation in anaplastic thyroid carcinoma via transcriptional regulation of cyclin A1: A paradigm shift that impacts existing therapeutic approaches. J. Cell Sci. 2012, 125, 4253263. 52. Yang, Y.; Wang, F.; Shi, C.; Zou, Y.; Qin, H.; Ma, Y. Cyclin D1 G870A polymorphism contributes to colorectal cancer susceptibility: Proof from a systematic overview of 22 case-control studies. PLoS 1 2012, 7, e36813. 53. Marchal, J.A.; Boulaiz, H.; Suarez, I.; Saniger, I.; Campos, J.; Carillo, E.; Prados, J.; Gallo, M.A.; Espinosa, A.; Ar ega, A. Growth inhibition, G1-arrest, and apoptosis in MCF-7 human breast cancer cells by novel highly lipophilic 5-fluorouracil derivatives. Investig. N. Drugs 2004, 22, 37989. 54. STATA/SE, version 12; computer software for statistical analyse; StataCorp LP: College Station, TX, USA, 2011. 2013 by the authors; licensee MDPI, Basel, Switzerland. This short article is definitely an open access short article di.